Mechanism of immunotherapeutic activity of OK-432 in the treatment of peritoneal carcinomatosis

Hiroyasu Fukui, Craig W. Reynolds, Barbara Lenz, Mark Schneider, James E Talmadge

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

In this report the mechanism of therapeutic activity of OK-432 for the treatment of peritoneal carcinomatosis was investigated by correlating effector-cell augmentation with therapeutic activity in rats bearing MADB-106 carcinomatosis. Tumor cells were injected i.p. and the treatment with OK-432 was initiated 5 days later with 0.5, 1, 5 or 10 KE/animal of OK-432 injected i.p. semiweekly. Significant therapeutic activity was observed at all doses examined with greater prolongation of survival noted at the higher doses of OK-432. Animals treated with 0.5 KE/animal had a prolongation of the median survival time from 14 days for saline-treated animals to 17 days for the OK-432 treated animals (P<0.0008), while animals treated with higher doses had much longer periods of survival, some animals being tumor-free at 185 days. In the same studies, natural killer (NK) cell, lymphokine-activated killer cell, cytotoxic T lymphocyte, and macrophage tumoricidal/cytostatic activities were measured 7 days and 14 days following tumor injection (2 days and 9 days after initiation of immunotherapy). OK-432 had immunostimulatory activity in most of the assays of immune function examined and this correlated with host survival, including augmentation of peritoneal and peripheral blood cytotoxic T lymphocyte activity on day 14, peritoneal and alveolar macrophage activity on day 7 and day 14, as well as natural killer cell activity on day 14. These results suggest that the therapeutic doses are also immunomodulatory doses for the effector cells mentioned above. We suggest, therefore, that immunological monitoring may help to optimize treatment protocols for the treatment of peritoneal and perhaps pleural effusions with OK-432.

Original languageEnglish (US)
Pages (from-to)1-6
Number of pages6
JournalCancer Immunology Immunotherapy
Volume29
Issue number1
DOIs
StatePublished - May 1 1989

Fingerprint

Picibanil
Carcinoma
Cytotoxic T-Lymphocytes
Natural Killer Cells
Therapeutics
Lymphokine-Activated Killer Cells
Immunologic Monitoring
Neoplasms
Alveolar Macrophages
Peritoneal Macrophages
Cytostatic Agents
Pleural Effusion
Clinical Protocols
Immunotherapy
Macrophages
Injections

ASJC Scopus subject areas

  • Oncology
  • Immunology
  • Cancer Research

Cite this

Mechanism of immunotherapeutic activity of OK-432 in the treatment of peritoneal carcinomatosis. / Fukui, Hiroyasu; Reynolds, Craig W.; Lenz, Barbara; Schneider, Mark; Talmadge, James E.

In: Cancer Immunology Immunotherapy, Vol. 29, No. 1, 01.05.1989, p. 1-6.

Research output: Contribution to journalArticle

Fukui, Hiroyasu ; Reynolds, Craig W. ; Lenz, Barbara ; Schneider, Mark ; Talmadge, James E. / Mechanism of immunotherapeutic activity of OK-432 in the treatment of peritoneal carcinomatosis. In: Cancer Immunology Immunotherapy. 1989 ; Vol. 29, No. 1. pp. 1-6.
@article{f0b7358b40ed4627a5cb82adfcb9b134,
title = "Mechanism of immunotherapeutic activity of OK-432 in the treatment of peritoneal carcinomatosis",
abstract = "In this report the mechanism of therapeutic activity of OK-432 for the treatment of peritoneal carcinomatosis was investigated by correlating effector-cell augmentation with therapeutic activity in rats bearing MADB-106 carcinomatosis. Tumor cells were injected i.p. and the treatment with OK-432 was initiated 5 days later with 0.5, 1, 5 or 10 KE/animal of OK-432 injected i.p. semiweekly. Significant therapeutic activity was observed at all doses examined with greater prolongation of survival noted at the higher doses of OK-432. Animals treated with 0.5 KE/animal had a prolongation of the median survival time from 14 days for saline-treated animals to 17 days for the OK-432 treated animals (P<0.0008), while animals treated with higher doses had much longer periods of survival, some animals being tumor-free at 185 days. In the same studies, natural killer (NK) cell, lymphokine-activated killer cell, cytotoxic T lymphocyte, and macrophage tumoricidal/cytostatic activities were measured 7 days and 14 days following tumor injection (2 days and 9 days after initiation of immunotherapy). OK-432 had immunostimulatory activity in most of the assays of immune function examined and this correlated with host survival, including augmentation of peritoneal and peripheral blood cytotoxic T lymphocyte activity on day 14, peritoneal and alveolar macrophage activity on day 7 and day 14, as well as natural killer cell activity on day 14. These results suggest that the therapeutic doses are also immunomodulatory doses for the effector cells mentioned above. We suggest, therefore, that immunological monitoring may help to optimize treatment protocols for the treatment of peritoneal and perhaps pleural effusions with OK-432.",
author = "Hiroyasu Fukui and Reynolds, {Craig W.} and Barbara Lenz and Mark Schneider and Talmadge, {James E}",
year = "1989",
month = "5",
day = "1",
doi = "10.1007/BF00199909",
language = "English (US)",
volume = "29",
pages = "1--6",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "1",

}

TY - JOUR

T1 - Mechanism of immunotherapeutic activity of OK-432 in the treatment of peritoneal carcinomatosis

AU - Fukui, Hiroyasu

AU - Reynolds, Craig W.

AU - Lenz, Barbara

AU - Schneider, Mark

AU - Talmadge, James E

PY - 1989/5/1

Y1 - 1989/5/1

N2 - In this report the mechanism of therapeutic activity of OK-432 for the treatment of peritoneal carcinomatosis was investigated by correlating effector-cell augmentation with therapeutic activity in rats bearing MADB-106 carcinomatosis. Tumor cells were injected i.p. and the treatment with OK-432 was initiated 5 days later with 0.5, 1, 5 or 10 KE/animal of OK-432 injected i.p. semiweekly. Significant therapeutic activity was observed at all doses examined with greater prolongation of survival noted at the higher doses of OK-432. Animals treated with 0.5 KE/animal had a prolongation of the median survival time from 14 days for saline-treated animals to 17 days for the OK-432 treated animals (P<0.0008), while animals treated with higher doses had much longer periods of survival, some animals being tumor-free at 185 days. In the same studies, natural killer (NK) cell, lymphokine-activated killer cell, cytotoxic T lymphocyte, and macrophage tumoricidal/cytostatic activities were measured 7 days and 14 days following tumor injection (2 days and 9 days after initiation of immunotherapy). OK-432 had immunostimulatory activity in most of the assays of immune function examined and this correlated with host survival, including augmentation of peritoneal and peripheral blood cytotoxic T lymphocyte activity on day 14, peritoneal and alveolar macrophage activity on day 7 and day 14, as well as natural killer cell activity on day 14. These results suggest that the therapeutic doses are also immunomodulatory doses for the effector cells mentioned above. We suggest, therefore, that immunological monitoring may help to optimize treatment protocols for the treatment of peritoneal and perhaps pleural effusions with OK-432.

AB - In this report the mechanism of therapeutic activity of OK-432 for the treatment of peritoneal carcinomatosis was investigated by correlating effector-cell augmentation with therapeutic activity in rats bearing MADB-106 carcinomatosis. Tumor cells were injected i.p. and the treatment with OK-432 was initiated 5 days later with 0.5, 1, 5 or 10 KE/animal of OK-432 injected i.p. semiweekly. Significant therapeutic activity was observed at all doses examined with greater prolongation of survival noted at the higher doses of OK-432. Animals treated with 0.5 KE/animal had a prolongation of the median survival time from 14 days for saline-treated animals to 17 days for the OK-432 treated animals (P<0.0008), while animals treated with higher doses had much longer periods of survival, some animals being tumor-free at 185 days. In the same studies, natural killer (NK) cell, lymphokine-activated killer cell, cytotoxic T lymphocyte, and macrophage tumoricidal/cytostatic activities were measured 7 days and 14 days following tumor injection (2 days and 9 days after initiation of immunotherapy). OK-432 had immunostimulatory activity in most of the assays of immune function examined and this correlated with host survival, including augmentation of peritoneal and peripheral blood cytotoxic T lymphocyte activity on day 14, peritoneal and alveolar macrophage activity on day 7 and day 14, as well as natural killer cell activity on day 14. These results suggest that the therapeutic doses are also immunomodulatory doses for the effector cells mentioned above. We suggest, therefore, that immunological monitoring may help to optimize treatment protocols for the treatment of peritoneal and perhaps pleural effusions with OK-432.

UR - http://www.scopus.com/inward/record.url?scp=0024543902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024543902&partnerID=8YFLogxK

U2 - 10.1007/BF00199909

DO - 10.1007/BF00199909

M3 - Article

VL - 29

SP - 1

EP - 6

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 1

ER -